3Farshad Abir,Suraj Alva, Walter E. Longo,et al. The postoperative surveillance of patients with colon cancer and rectal cancer [J ]. American Journal of Surgery, 2006,192 (1): 100-108.
4Rufford BD,Jacobs IJ ,Menon U. Feasibility of screening for ovarian cancer using symptoms as selection criteria [J]. BJOG : An International Journal of Obstetrics and Gynaecology, 2007,114 (1): 59-64.
5Makoto OKADA, Kimihiro SUZUKI, Takashi NAKANISHI, et al. Serum levels of KL-6 are positively correlated with those of CA15-3 in patients with interstitial pneumonia associated with collagen diseases[J]. Respirology,2006,11 (3) : 509-510.
6CHUNG-MOU KUO, CHI-SIN CHANGCHIEN, KENG-LIANG WU,et al. Mucin-producing cholangiocarcinoma: Clinical experience of 24 cases in 16 years[J]. Scandinavian Journal of Gastroenterology, 2006,55 (8) : 455-459.
7Shinjiro Mizuguchi, Noritoshi Nishiyama, Takashi Iwata, et al. Clinical Value of Serum Cytokeratin 19 Fragment and Sialyl- Lewis X in Non-Small Cell Lung Cancer[J]. Annals of Thoracic Surgery, 2007,38 (1) : 216-221.
9Asif Zubair Bhatti,Saima Asif, Majeed Alwan. Factors Affecting Incomplete Excision of Nonmelanoma Skin Cancers in New Zealand[J]. Annals of Plastic Surgery, 2006,57(5) : 513-516.
10Carsten Stephan ,Greta Stroebel, Marc Heinau ,et al. The Ratio of Prostate-Specific Antigen (PSA) to Prostate Volume (PSA Density) as a Parameter to Improve the Detection of Prostate Carcinoma in PSA Values in the Range of <4 ng/ml[J]. Cancer, 2005,104 (5) : 993-1003.
4Shitrit D, Zingerman B, Shitrit AB, et al. Diagnostic value of CYFRA 21-1, CEA, CA 19-9,CA 15-3, and CA 125 assays. in pleural effusions: analysis of 116 cases and review of the literature. Oncologist, 2005,10(7) :501-507.
5Tamura M, Ohta Y, Nakamura H, et al. Diagnostic value of plasma vascular endothelial growth factor as a tumor marker in patients with non-small cell lung cancer. Int J Biol Markers, 2002,17(4) :275-297.
6Kido Y. Vascular endothelial growth factor(VEGF) serum concentration changes during chemotherapy in patients with lung cancer. Kurume Med J, 2001,48 ( 1 ) :43-47.
7Niklinska W, Burzykowski T, Chyczewski LO, et al. Expression of vascular endothelial growth factor (VEGF) in non-small cell lung cancer (NSCLC) : association with p53 gene mutation and prognosis. Lung Cancer, 2001,34( Suppl 2) : S59-64.
8Park SH, Lee SS. The relationship between serum VEGF concentration and prognosis of lung cancer. Korean J Intern Med, 2003,18(4) :207-211.
9Hoekstra R, Eskens FA, Verweij J. Matrix metalloproteinase inhibitors: current developments and future perspectives.Oncologist, 2001,6(5) :415-416.
10Ylisimio S, Hoyhtya M, Makitaro R, et al. Elevated serum levels of type Ⅰ collagen degradation marker ICTP and tissue inhibitor of metalloproteinase (TIMP) 1 are associated with poor prognosis in lung cancer. Clin Cancer Res, 2001,7(76) :1633-1637.
5Matter R, Andrade CR, Difavero GM, et al. Preoperative serum levels of CA72-4,CEA, CA19-9 and alpha-fetoprotein in patients with gastic cancer[J]. Rev Hosp Clin Fac Med Uni Sao Paulo, 2002,57 (3) : 89-92.
6Gaspar MJ, Amibas I, Coca MC,et al. Prognostic value of carcinoembryonic antigen CA19-9 and CA72 4 in gastric carcinoma[J]. Tumour Biol,2001,22(5) 1318-322.
7Ozsahln S L, Turgut B, Nur N,et al. Validity of the CA12-5 level in the differential diagnosis of pulmonary tuberalosis [J]. Jpn J Infect Dis,2008,61(1):68-69.
